| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
President and CEO | Chief Executive Officer | Director
2 companies
Marianne De Backer is President and CEO at VIR and has filed Form 4s across 2 companies. Marianne De Backer's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $5.1M at current prices.
Historically, Marianne De Backer's trades have earned a middling insider score of 67/100 across 8 rated trades. Over a 12-month horizon, 60.0% of those trades were profitable, with an average 12-month return of +18.7%.
The biggest single holding is VIR (~$3.2M) as President and CEO. The VIR filings lean toward selling, a net 275,189 shares.
Marianne De Backer has 18 Form 4 filings on record from January 2020 to April 2026, across 2 companies: President and CEO at Vir Biotechnology (VIR), 2023–2026; Director at Arrowhead Pharmaceuticals (ARWR), 2020–2023.
The 37 reported transactions were 10 open-market sales, 10 open-market purchases, 8 stock awards and 5 option or other derivative awards, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 2 purchases worth about $185K and 8 sales worth about $3.0M.
The largest open-market purchase was 4,000 shares of ARWR at an average $33.56 on June 15, 2020, about $134K.
The largest open-market sale was 72,995 shares of VIR at an average $9.46 on April 3, 2024, about $690K. Twelve months later VIR was down 38%.
All 6 sales since April 2023 were made under a Rule 10b5-1 trading plan, set up in advance.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr 6, 2026 | VIR Vir Biotechnology, Inc. | President and CEO | Sell10b5-1 | 72,559 | $9.16 | $664,350.20 | -7.1% | +10.6% | - | |
| Feb 24, 2026 | VIR Vir Biotechnology, Inc. | Chief Executive Officer | Sell10b5-1 | 14,762 | $9.53 | $140,720.24 | -1.4% | -1.2% | - | |
| Feb 23, 2026 | VIR Vir Biotechnology, Inc. | Chief Executive Officer | Sell10b5-1 | 19,039 | $7.45 | $141,893.86 | -1.8% | +26.2% | - | |
| Apr 3, 2025 | VIR Vir Biotechnology, Inc. | Chief Executive Officer | Sell10b5-1 | 79,712 | $5.95 | $474,238.57 | -9.4% | -8.9% | +51.3% | |
| Feb 24, 2025 | VIR Vir Biotechnology, Inc. | Chief Executive Officer | Sell10b5-1 | 16,122 | $9.45 | $152,407.71 | -1.9% | -50.8% | +0.2% | |
| Apr 3, 2024 | VIR Vir Biotechnology, Inc. | Chief Executive Officer | Sell10b5-1 | 72,995 | $9.46 | $690,364.81 | -9.7% | -8.7% | -38.5% | |
| Jan 3, 2022 | ARWR Arrowhead Pharmaceuticals, Inc. | Director | Sell | 4,500 | $64.71 | $291,176.84 | -20.9% | -27.7% | -45.0% | |
| Jun 24, 2021 | ARWR Arrowhead Pharmaceuticals, Inc. | Director | Sell | 5,000 | $89.85 | $449,250.00 | -18.9% | -29.9% | -61.5% | |
| Oct 8, 2020 | ARWR Arrowhead Pharmaceuticals, Inc. | Director | Buy | 1,000 | $50.47 | $50,465.00 | +6.1% | - | - | |
| Jun 15, 2020 | ARWR Arrowhead Pharmaceuticals, Inc. | Director | Buy | 4,000 | $33.56 | $134,240.00 | +32.0% | - | - |